Clinical Trial of Autologous Differentiated Adipocytes from Stem Cells Derived from Human Adipose Tissue

Kim, Mihyung; Kim, Inok; Lee, Sung Koo; Bang, Sa Ik; Lim, So Young

doi:10.1111/j.1524-4725.2011.01765.x

Cited by 54 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…*P < 0.05. trials. 15 The clinical applicability of hASCs spans all agegroups. Some studies have shown the effects of age on the proliferative and differentiation potentials of hASCs.…”

Section: Discussionmentioning

confidence: 99%

Adipose-derived mesenchymal stem cells from the elderly exhibit decreased migration and differentiation abilities with senescent properties

et al. 2017

View full text Add to dashboard Cite

Adipose-derived stem cells (ASCs) can be applied extensively in the clinic because they can be easily isolated and cause less donor-site morbidity; however, their application can be complicated by patient-specific factors, such as age and harvest site. In this study, we systematically evaluated the effects of age on the quantity and quality of human adipose-derived mesenchymal stem cells (hASCs) isolated from excised chest subcutaneous adipose tissue and investigated the underlying molecular mechanism. hASCs were isolated from donors of 3 different age-groups (i.e., child, young adult, and elderly). hASCs are available from individuals across all age-groups and maintain mesenchymal stem cell (MSC) characteristics. However, the increased age of the donors was found to have a significant negative effect on hASCs frequency base on colony-forming unit fibroblasts assay. Moreover, there is a decline in both stromal vascular fraction (SVF) cell yield and the proliferation rate of hASCs with increasing age, although this relationship is not significant. Aging increases cellular senescence, which is manifested as an increase in SA-b-gal-positive cells, increased mitochondrial-specific reactive oxygen species (ROS) production, and the expression of p21 in the elderly. Further, advancing age was found to have a significant negative effect on the adipogenic and osteogenic differentiation potentials of hASCs, particularly at the early and mid-stages of induction, suggesting a slower response to the inducing factors of hASCs from elderly donors. Finally, impaired migration ability was also observed in the elderly group and was determined to be associated with decreased expression of chemokine receptors, such as CXCR4 and CXCR7. Taken together, these results suggest that, while hASCs from different age populations are phenotypically similar, they present major differences at the functional level. When considering potential applications of hASCs in cell-based therapeutic strategies, the negative influence of age on hASC differentiation potential and migration abilities should be taken seriously.

show abstract

“…*P < 0.05. trials. 15 The clinical applicability of hASCs spans all agegroups. Some studies have shown the effects of age on the proliferative and differentiation potentials of hASCs.…”

Section: Discussionmentioning

confidence: 99%

Adipose-derived mesenchymal stem cells from the elderly exhibit decreased migration and differentiation abilities with senescent properties

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The cells were negative for the expression of the hematopoietic stem cell-associated markers CD34 and CD45 and the bone marrow-derived stem cell-associated marker STRO-1 [26]. Furthermore, genomic stability of ASCs was evaluated by karyotyping analysis and no evidence of tumor formation was observed in tumorigenicity study carried out with immunecompromised nude mice after repeated administration of cells.…”

Section: Preparation Of Ascsmentioning

confidence: 99%

Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula

Lee¹,

Park²,

Cho³

et al. 2013

Stem Cells

Self Cite

250

203

View full text Add to dashboard Cite

Fistula is a representative devastating complication in Crohn's patients due to refractory to conventional therapy and high recurrence. In our phase I clinical trial, adipose tissue-derived stem cells (ASCs) demonstrated their safety and therapeutic potential for healing fistulae associated with Crohn's disease. This study was carried out to evaluate the efficacy and safety of ASCs in patients with Crohn's fistulae. In this phase II study, forty-three patients were treated with ASCs. The amount of ASCs was proportioned to fistula size and fistula tract was filled with ASCs in combination with fibrin glue after intralesional injection of ASCs. Patients without complete closure of fistula at 8 weeks received a second injection of ASCs containing 1.5 times more cells than the first injection. Fistula healing at week 8 after final dose injection and its sustainability for 1-year were evaluated. Healing was defined as a complete closure of external opening without any sign of drainage and inflammation. A modified per-protocol analysis showed that complete fistula healing was observed in 27/33 patients (82%) by 8 weeks after ASC injection. Of 27 patients with fistula healing, 26 patients completed additional observation study for 1-year and 23 patients (88%) sustained complete closure. There were no adverse events related to ASC administration. ASC treatment for patients with Crohn's fistulae was well tolerated, with a favorable therapeutic outcome. Furthermore, complete closure was well sustained. These results strongly suggest that autologous ASC could be a novel treatment option for the Crohn's fistula with high-risk of recurrence. STEM

show abstract

“…Although, autologous fat grafts including ADSC [25] are in current clinical practice, their long-term graft retention [26] [27][28][29][30]. Alternatively, Kim and his coworkers were successful in transplanting the differentiating adipocytes from ADSC for treating depressed scar with up to 75 % success rate [31]. Developing strategies to reconstruct larger tissue defects, however, remains a formidable challenge.…”

Section: Soft Tissue Defectsmentioning

confidence: 99%

Adipose-Derived Stem Cells: In Musculoskeletal Disorders

Dhanasekaran¹,

Kotturu

Behera

et al. 2014

Stem Cell Therapy for Organ Failure

View full text Add to dashboard Cite

Clinical Trial of Autologous Differentiated Adipocytes from Stem Cells Derived from Human Adipose Tissue

Abstract: The use of autologous differentiated adipocytes can be a safe and effective treatment for soft tissue defects, with relatively long-term maintenance of volume. The authors have indicated no significant interest with commercial supporters.

Cited by 54 publications

References 19 publications

Adipose-derived mesenchymal stem cells from the elderly exhibit decreased migration and differentiation abilities with senescent properties

Adipose-derived mesenchymal stem cells from the elderly exhibit decreased migration and differentiation abilities with senescent properties

Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for Crohn's fistula

Adipose-Derived Stem Cells: In Musculoskeletal Disorders

Contact Info

Product

Resources

About